Buprenorphine for Chronic Pain After an Accident: What PI Patients Need to Know

James Wong — Founder & Pharmacist, LienScripts | February 12, 2026 | 8 min read

Low-dose buprenorphine (Belbuca, Butrans) is prescribed by pain management physicians for PI patients with chronic pain — not addiction treatment. Learn how pharmacy liens cover buprenorphine when insurance requires prior authorization.

Buprenorphine in Chronic Pain Management: Beyond the Addiction Narrative

When most people hear "buprenorphine," they think of addiction treatment — Suboxone, medication-assisted treatment (MAT) for opioid use disorder. This association, while accurate in one clinical context, obscures a separate and growing role for buprenorphine in chronic pain management that is directly relevant to personal injury patients.

Low-dose buprenorphine formulations — specifically Belbuca (buprenorphine buccal film) and Butrans (buprenorphine transdermal patch) — are FDA-approved for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. These are not addiction treatment products. They are Schedule III controlled substances prescribed by pain management physicians for patients with chronic pain that has not responded adequately to non-opioid therapies.

For personal injury patients who sustain serious injuries requiring long-term pain management, buprenorphine has become an important tool in the prescriber's arsenal — and understanding it helps both patients and their attorneys navigate the treatment landscape.

The Pharmacology: Why Buprenorphine Is Unique

Buprenorphine is a partial mu-opioid receptor agonist with a ceiling effect on respiratory depression — the mechanism responsible for opioid overdose fatalities. Unlike full agonist opioids such as oxycodone, hydrocodone, or morphine, buprenorphine's partial agonism means that increasing the dose beyond a certain point does not proportionally increase respiratory depression. This makes it a substantially safer opioid option for long-term use in chronic pain management.

Buprenorphine also has a very high binding affinity for opioid receptors. Once it binds, it stays — providing long-duration analgesia that makes it suitable for around-the-clock dosing via patch (Butrans, replaced weekly or every 7 days) or twice-daily buccal film (Belbuca).

Additionally, buprenorphine has demonstrated activity at kappa and delta opioid receptors and the nociceptin receptor, which may contribute to its effectiveness in neuropathic pain conditions — a profile that matters for PI patients with nerve injury or central sensitization.

[!SOURCE] The FDA approved Butrans (buprenorphine transdermal) in 2010 and Belbuca (buprenorphine buccal film) in 2015 specifically for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. See the FDA prescribing information for each product at fda.gov.

DEA Scheduling: Schedule III, Not Schedule II

A key distinction that matters clinically and legally is that buprenorphine formulations for pain (Butrans, Belbuca) are classified as DEA Schedule III controlled substances. This is one schedule lower in restriction than the full agonist opioids (Schedule II: oxycodone, hydrocodone, fentanyl, morphine), which require a new written prescription for every fill with no refills allowed.

Schedule III status means that buprenorphine for pain can be prescribed with up to five refills within six months, can be called in by phone, and is subject to less restrictive prescribing requirements. This matters practically: a PI patient managing chronic pain can have their prescription called in rather than requiring an in-person visit for every refill — an important convenience during a period when they may have mobility limitations or transportation challenges.

This is distinct from buprenorphine/naloxone products (Suboxone, Zubsolv) used for opioid use disorder treatment, which require a separate DEA waiver (X-waiver) for prescribing — a regulatory distinction that sometimes causes confusion.

When Pain Management Physicians Choose Buprenorphine for PI Patients

Pain management specialists select buprenorphine for chronic pain management in PI patients for several overlapping clinical reasons:

Opioid rotation — When a patient has been on full agonist opioids (oxycodone, hydrocodone) for an extended period and is experiencing diminishing analgesic benefit, tolerance, or side effects, rotating to buprenorphine can restore pain control with a different pharmacological profile.

Opioid-induced hyperalgesia — Paradoxically, long-term opioid use can increase pain sensitivity. Buprenorphine may help reset this process due to its partial agonist profile and receptor binding characteristics.

Safety-driven prescribing — For patients with risk factors for respiratory depression (sleep apnea, COPD, concomitant benzodiazepine use), the ceiling effect on buprenorphine's respiratory effects makes it a safer long-term choice than full agonist opioids.

Neuropathic pain — For PI patients with nerve injury, CRPS, or central sensitization, buprenorphine's multimodal receptor activity can provide broader pain coverage than traditional opioids.

Long-term injury management — Serious PI injuries — spinal cord damage, traumatic amputations, complex orthopedic trauma — may require months or years of opioid management. Buprenorphine's favorable long-term safety profile makes it a logical choice for extended treatment.

[!KEY] When a pain management physician transitions a PI patient from a Schedule II opioid to buprenorphine, this is a clinical decision reflecting the physician's judgment about long-term safety and efficacy. It should not be interpreted — by the patient, insurer, or opposing counsel — as evidence of addiction or substance misuse. The prescription context (pain management, not addiction treatment) and the specific formulation (Belbuca or Butrans, not Suboxone) are key differentiators.

Why Insurance Denies Buprenorphine for Pain in PI Cases

Despite FDA approval and Schedule III status, buprenorphine for chronic pain faces significant insurance coverage barriers:

Prior authorization — Nearly all commercial insurers require prior authorization for Belbuca and Butrans, typically requiring documented failure of multiple other opioids and/or non-opioid pain therapies.

Step therapy — Insurers may require a patient to try (and fail) less expensive medications before approving buprenorphine for pain, even when the prescribing physician has determined that buprenorphine is clinically appropriate.

Formulary exclusion — Some insurance formularies do not include the branded pain formulations of buprenorphine, or place them in high-cost tiers requiring substantial patient cost-sharing.

Confusion with MAT — Some insurance systems may flag buprenorphine prescriptions for review based on the drug's association with addiction treatment, creating administrative delays or denials that require physician intervention to resolve.

In personal injury cases, these barriers are compounded by the reality that health insurance may not be actively coordinating with the PI claim, and the patient may have limited bandwidth to navigate appeals while managing a serious injury and litigation.

How Pharmacy Liens Cover Buprenorphine

A pharmacy lien program resolves the insurance barrier by dispensing the prescribed medication on credit, secured against the future settlement or judgment. When a pain management physician prescribes Belbuca or Butrans for a PI patient and the insurance company denies coverage or requires a prior authorization process that would delay treatment, the pharmacy lien provides immediate access.

The patient receives their medication. The lien accrues against the case. Repayment occurs at settlement.

This mechanism is particularly valuable for buprenorphine because the medication's benefits depend on consistent, uninterrupted use. Missing doses due to insurance delays or cost barriers can disrupt pain control and potentially precipitate withdrawal symptoms in patients who have been on the medication for extended periods.

[!KEY] Attorneys should note that pharmacy lien records for buprenorphine for pain — clearly showing the prescribing physician's specialty (pain management), the specific formulation (Belbuca or Butrans), and the clinical context — are important documents for the demand package. They demonstrate that the patient required long-term, daily opioid management for their injuries and that the injury was severe enough to justify this level of intervention.

Documentation Considerations for Attorneys

When buprenorphine for chronic pain appears in a PI file, the demand package should include:

• Pain management specialist records explaining the indication and rationale for buprenorphine over alternatives
• Prior authorization denial letters or documentation of insurance barriers
• Pharmacy lien dispensing records showing consistent fills and the ongoing nature of treatment
• Functional assessments or pain scores documenting the patient's degree of impairment

Together, these documents communicate that the patient's injuries required sustained, physician-managed opioid therapy of a level typically reserved for serious chronic pain conditions — a fact with direct relevance to both special and general damages.

Related Resources

• Opioid Prescribing Guidelines in Personal Injury Cases
• Oxycodone Alternatives for Complex Injury Pain
• Pain Management Doctor and Pharmacy Lien Coordination
• Spinal Cord Injury Medications: Long-Term Management
• What Is a Pharmacy Lien?